MX2019002382A - Anticuerpos anti-gremlin-1 (grem1) y metodos de uso de los mismos para tratar la hipertension arterial pulmonar. - Google Patents

Anticuerpos anti-gremlin-1 (grem1) y metodos de uso de los mismos para tratar la hipertension arterial pulmonar.

Info

Publication number
MX2019002382A
MX2019002382A MX2019002382A MX2019002382A MX2019002382A MX 2019002382 A MX2019002382 A MX 2019002382A MX 2019002382 A MX2019002382 A MX 2019002382A MX 2019002382 A MX2019002382 A MX 2019002382A MX 2019002382 A MX2019002382 A MX 2019002382A
Authority
MX
Mexico
Prior art keywords
subject
grem1
gremlin
antibodies
antigen
Prior art date
Application number
MX2019002382A
Other languages
English (en)
Inventor
C Morton Lori
Chalothorn Dan
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MX2019002382A publication Critical patent/MX2019002382A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invencion proporciona anticuerpos anti-Gremlin-1 (GREM1), y sus fragmentos de union a antigeno, asi como metodos de uso de tales anticuerpos, o sus fragmentos de union a antigeno, para tratar un sujeto que tiene hipertension arterial pulmonar (PAH); se describe un metodo para tratar un sujeto que tiene hipertension arterial pulmonar (PAH), que comprende administrar al sujeto una cantidad terapeuticamente eficaz de un anticuerpo antigremlin-1 (GREM1), o su fragmento de union a antigeno, en donde el efecto terapeutico de administracion del anticuerpo anti-GREM1, o su fragmento de union a antigeno, al sujeto se selecciona del grupo que consiste en inhibir el engrosamiento de la arteria pulmonar en el sujeto; aumentar el volumen sistolico en el sujeto; aumentar el gasto cardiaco del ventriculo derecho en el sujeto; y extender el tiempo de supervivencia del sujeto, tratando de esta manera el sujeto que tiene PAH.
MX2019002382A 2016-08-29 2017-08-23 Anticuerpos anti-gremlin-1 (grem1) y metodos de uso de los mismos para tratar la hipertension arterial pulmonar. MX2019002382A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662380562P 2016-08-29 2016-08-29
PCT/US2017/048137 WO2018044640A1 (en) 2016-08-29 2017-08-23 Anti-gremlin-1 (grem1) antibodies and methods of use thereof for treating pulmonary arterial hypertension

Publications (1)

Publication Number Publication Date
MX2019002382A true MX2019002382A (es) 2019-06-20

Family

ID=59791160

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019002382A MX2019002382A (es) 2016-08-29 2017-08-23 Anticuerpos anti-gremlin-1 (grem1) y metodos de uso de los mismos para tratar la hipertension arterial pulmonar.

Country Status (12)

Country Link
US (1) US20180057580A1 (es)
EP (1) EP3504238A1 (es)
JP (1) JP2019529371A (es)
KR (1) KR20190040320A (es)
CN (1) CN109641954A (es)
AU (1) AU2017320989A1 (es)
CA (1) CA3031783A1 (es)
EA (1) EA201990613A1 (es)
IL (1) IL264309A (es)
MA (1) MA46046A (es)
MX (1) MX2019002382A (es)
WO (1) WO2018044640A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3574017A1 (en) 2017-01-27 2019-12-04 Kymab Limited Anti-opg antibodies
JP2024504124A (ja) * 2021-01-18 2024-01-30 スーチョウ・トランスセンタ・セラピューティクス・カンパニー・リミテッド 新規の抗グレムリン１抗体
AU2023258146A1 (en) * 2022-04-20 2024-09-05 Kantonsspital St. Gallen Antibodies or antigen-binding fragments pan-specifically binding to gremlin-1 and gremlin-2 and uses thereof
CN117801109B (zh) * 2024-03-01 2024-05-03 再少年(北京)生物科技有限公司 iPS诱导定向分化成内皮祖细胞的方法及应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2437213A1 (fr) 1978-09-28 1980-04-25 Cm Ind Produits cytotoxiques formes par liaison covalente de la chaine a de la ricine avec un anticorps et leur procede de preparation
US6573096B1 (en) 2000-04-01 2003-06-03 The Research Foundation At State University Of New York Compositions and methods for inhibition of cancer invasion and angiogenesis
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
WO2005103081A2 (en) 2004-04-20 2005-11-03 Genmab A/S Human monoclonal antibodies against cd20
US7411046B2 (en) 2005-08-02 2008-08-12 Arius Research Inc Cancerous disease modifying antibodies
US7420041B2 (en) 2006-02-24 2008-09-02 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of TROP-2
JP6305345B2 (ja) * 2011-12-12 2018-04-04 ピエリス ファーマシューティカルズ ゲーエムベーハー 鉄および関連する薬学的製剤のバイオアベイラビリティを増加させることによる障害の予防または治療方法
US20150272874A1 (en) * 2012-10-29 2015-10-01 Cardio Incorporated Pulmonary disease-specific therapeutic agent
US10377817B2 (en) * 2013-03-14 2019-08-13 Regeneron Pharmaceuticals, Inc. Human antibodies to GREM1

Also Published As

Publication number Publication date
MA46046A (fr) 2019-07-03
KR20190040320A (ko) 2019-04-17
US20180057580A1 (en) 2018-03-01
IL264309A (en) 2019-02-28
CA3031783A1 (en) 2018-03-08
AU2017320989A1 (en) 2019-02-07
EP3504238A1 (en) 2019-07-03
JP2019529371A (ja) 2019-10-17
EA201990613A1 (ru) 2019-07-31
CN109641954A (zh) 2019-04-16
WO2018044640A1 (en) 2018-03-08
AU2017320989A9 (en) 2019-07-11

Similar Documents

Publication Publication Date Title
EA201890145A1 (ru) Антитела к фактору xi и способы их применения
MX2023014569A (es) Anticuerpos anti-sirpa.
PH12018501220A1 (en) Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof
MX2019002382A (es) Anticuerpos anti-gremlin-1 (grem1) y metodos de uso de los mismos para tratar la hipertension arterial pulmonar.
UA118453C2 (uk) Спосіб лікування пухлин у пацієнта
MX2022008523A (es) Compuestos que interactuan con glicanos y metodos de uso.
EA201890305A1 (ru) Гуманизированные или химерные cd3-антитела
MX2022014914A (es) Compuestos de interaccion con glicanos y metodos de uso.
MX2019009117A (es) Anticuerpos anti alfa-sinucleina y usos de los mismos.
EA201790305A1 (ru) КОМБИНИРОВАННАЯ ТЕРАПИЯ БОЛЕЗНИ АЛЬЦГЕЙМЕРА С ИСПОЛЬЗОВАНИЕМ КОМБИНАЦИИ МОНОКЛОНАЛЬНЫХ АНТИТЕЛ К N3pGlu АБЕТА И ИНГИБИТОРА BACE
MX2022003005A (es) Composiciones y metodos de anticuerpos anti-cd39.
ZA202202363B (en) Antibodies against ilt2 and use thereof
NZ754676A (en) Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta
MX2020008122A (es) Anticuerpos anti-pd-1.
MX2019001958A (es) Metodos para tratar la enfermedad de crohn con un anticuerpo anti-nkg2d.
EA202190807A1 (ru) Антитела к синуклеину
MX2022002635A (es) Anticuerpos anti proteina similar a angiopoyetina 4 y metodos de uso.
MX2022006073A (es) Metodos para utilizar anticuerpos anti-trem2.
TW201613977A (en) Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
EP4279925A3 (en) Dulaglutide for the treatment of chronic kidney disease
ZA202001568B (en) Methods and compositions for treating chronic lung diseases
ZA202110285B (en) Antibodies and methods of use
EA202090266A1 (ru) Ингибиторы mpo для применения в медицине
MX2021004356A (es) Formulaciones de anticuerpos anti-rsv y metodos de uso de las mismas.
MX2019014090A (es) Métodos para el tratamiento de la reservoritis crónica.